The Journey of <i>in vivo</i> Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.

Front Immunol · 2018 · PMC6141723 · PMID 30254636

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

When the immune responses generated with AVX701 in colorectal cancer patients were compared between stage III and IV patients, the latter showed a trend for longer survival.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.